https://www.thebodypro.com/collection/ias-2019
Full panel for HIV Treatment Research: New Drugs and More Efficient Regimens press conference
Conference Coverage

What's New in HIV Treatment: A Report on Updates from IAS 2019

Researchers reported hopeful news on regimens with lower treatment burdens and newly developed antiretrovirals.

Featured

Asa Radix at IAS 2019
Conference Coverage

Taking Transgender Care From Research to Results

Asa Radix, M.D., M.P.H., discusses providing quality care to transgender people. It can be done.

Indigenous Protesters at IAS 2019
Conference Coverage

Indigenous Communities in Mexico and Elsewhere Demand a Seat at the Table

"We have never been silent, but you have not heard us": Advocates demonstrate to demand inclusion of indigenous issues in the HIV response.

Samuel J. Bunting
Conference Coverage

Getting PrEP to People by Training Entire Health Teams

Primary care providers need more education when it comes to PrEP, not only for them, but also for patients, who often think they need to see a specialist just to take this preventative medicine.

Jared Baeten
Conference Coverage

What Does the HOPE Study Say About the Future of the Vaginal Ring for HIV Prevention?

The results were less favorable than expected, but experts -- and women who participated in the trial -- would like to see this prevention tool approved for use.

Participants at the IAS 2019 Community Forum
Conference Coverage

Marginalized Groups Are Focus of IAS 2019 Forum

Activists working on human rights discuss the challenges of achieving an end to the HIV epidemic.

Christoph D. Spinner
Conference Coverage

DISCOVER PrEP Trial Finds F/TAF Has Superior Load Time and Tail Compared to F/TDF

But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.

Ivana Beesham
Conference Coverage

Experts Flummoxed By Conflicting New Data on STIs, HIV, and Long-Term Contraception in Sub-Saharan Africa

ECHO trial results and follow-up studies find unexpectedly low rates of some STIs among users of certain long-term hormonal contraceptives. They also find high HIV rates (unrelated to the contraceptives) that suggest considerable value for PrEP integration.

Fernanda Fernandes Fonseca and Meg Doherty at an IAS 2019 press conference
News

World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy

New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.

Doctors consultation
News

Having Fallen Out of Care, Most Gay and Bisexual Men With Detectable HIV Viral Loads Were Successfully Reconnected, Study Finds

The study enrolled more than a thousand people in four U.S. cities: Atlanta, Baltimore, Birmingham, and Boston.